You are here

Inflammation and Immunology


Pfizer is a global leader in developing medicines for patients suffering from chronic immune diseases. Pfizer is committed to the discovery and development of novel therapeutics to help patients living with chronic autoimmune diseases. The Inflammation & Immunology Research Unit is focused on discovering, evolving and developing the next generation of therapies for immune- mediated diseases. Pfizer is interested in entering into strategic relationships with innovative collaborators to develop increasingly novel and differentiated therapies for autoimmune diseases.

We are interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:

  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Inflammatory GI disorders (i.e., Inflammatory Bowel Disease)
  • Nonalcoholic steatohepatitis (NASH)
  • Atopic Dermatitis
  • Other indications with high unmet need that are mechanistically related to those above

Specific areas of interest include:

  • Cytokines and their signaling pathways
  • Adaptive Immunity, Lymphocyte biology including Th17 lymphocytes
  • Regulatory cells and Tolerance induction
  • Host-microbial interactions and microbiome with an interest in epithelial barrier
  • Innate Immunity and Innate Lymphoid Cell biology
  • Oxidative stress modulators
  • Anti-fibrotics
  • Technology platforms and products to help understand patient segmentation in the disease areas of interest and develop precision medicine strategies for innovative portfolio products
  • Technology platforms and products that allow for greater tissue and cell specific delivery

Not actively seeking partnering opportunities in:

  • TNFα, IL-1ß targeting biologics
  • B cell depleting biologics
  • Corticosteroids